Clinical trials: Retinal Disease
Adult Rhabdomyosarcoma, Adult Synovial Sarcoma
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors
This phase II trial is studying the side effects and how well cixutumumab works in treating patients with relapsed or refractory solid tumors. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways.
- Conditions
- Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Childhood Hepatoblastoma, Childhood Synovial Sarcoma
- Trial name
- NCT00831844
- Testing
- cixutumumab, laboratory biomarker analysis
- Where
- 105 sites in United States, Australia and 1 more
- Volunteers
- 116 people
- Sponsor
- National Cancer Institute (NCI)
Diabetic Macular Edema
A Multicenter Study to Compare Multiple Doses of Intravitreal Microplasmin Versus Sham Injection for Treatment of Patients With Diabetic Macular Edema (DME)
A multicenter study to compare multiple doses of intravitreal microplasmin for non-surgical PVD induction for treatment of patients with DME.
- Trial name
- MIVI-II (NCT00412451)
- Testing
- ocriplasmin
- Where
- 15 sites in Belgium, Germany and 4 more
- Volunteers
- 51 people
- Sponsor
- ThromboGenics
Leber Congenital Amaurosis 10, Blindness
Extension Study to Study PQ-110-001 (NCT03140969)
Subjects completing participation in study PQ-110-001 (EudraCT 2017-000813-22 / NCT03140969) will be given the opportunity to enroll into the extension study for continued dosing if available data support current and/or future…
- Conditions
- Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Vision Disorders
- Trial name
- INSIGHT (NCT03913130)
- Testing
- QR-110
- Where
- 3 sites in United States, Belgium
- Volunteers
- 9 people
- Sponsor
- Laboratoires Thea
Retinopathy of Prematurity (ROP)
Long-term Safety and Efficacy Outcome Study Comparing Children Previously Enrolled in Study ROPP-2008-01 for the Prevention of Retinopathy of Prematurity (ROP)
The main purpose of this study is to evaluate the long-term efficacy and safety outcomes following short-term exposure to rhIGF-1/rhIGFBP-3 versus standard neonatal care in Study ROPP-2008-01 (NCT01096784).
- Trial name
- PEDAL (NCT02386839)
- Testing
- rhIGF-1/rhIGFBP-3
- Where
- 16 sites in United States, Italy and 4 more
- Volunteers
- 76 people
- Sponsor
- Shire
Leber Congenital Amaurosis
Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis
The purpose of the study is to evaluate the safety and efficacy of an adeno-associated virus vector expressing RPE65 in patients with Leber congenital amaurosis caused by mutations in the RPE65 gene. Funding Source - FDA OOPD
- Trial name
- NCT00749957
- Testing
- rAAV2-CB-hRPE65
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Beacon Therapeutics
Macular Edema, Retinal Vein Occlusion
Study of Ozurdex® Treatment Practice in Patients With Macular Oedema Due to Retinal Vein Occlusion
Epidemiological study of Ozurdex® in sites treating patients with retinal vein occlusion.
- Trial name
- NCT01618266
- Testing
- dexamethasone intravitreal implant
- Where
- France
- Volunteers
- 375 people
- Sponsor
- Allergan
Age-Related Macular Degeneration
Safety and Exploratory Efficacy Study of SF0166 in the Treatment of Neovascular Age-Related Macular Degeneration (AMD)
The primary purpose of this study was to evaluate the safety and exploratory efficacy of SF0166 Topical Ophthalmic Solution in patients with Neovascular (wet) Age-related Macular Degeneration (AMD).
- Trial name
- NCT02914639
- Testing
- SF0166 Topical Ophthalmic Solution
- Where
- 12 sites in United States
- Volunteers
- 44 people
- Sponsor
- OcuTerra Therapeutics, Inc.
Exudative Age-Related Macular Degeneration
LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration
The purpose of this study is to evaluate the efficacy of 84 successive days of topically administered LHA510 compared to vehicle in reducing the number of patients requiring intravitreal (IVT) anti-vascular endothelial growth…
- Trial name
- NCT02355028
- Testing
- LHA510 ophthalmic suspension, LHA510 vehicle, Ranibizumab ophthalmic solution
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Alcon, a Novartis Company
Age-Related Macular Degeneration, Geographic Atrophy
Sirolimus for Advanced Age-Related Macular Degeneration
This study will determine whether a drug called sirolimus is safe to give to people with geographic atrophy (GA) and if it can help preserve vision in patients.
- Trial name
- SIRGA2 (NCT01445548)
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Eye Institute (NEI)
Neovascular Age-related Macular Degeneration, Age-related Macular Degeneration
SD-OCT Angiography
The objective of this study is to image retinal vascular alterations in patients with retinal disease using the AngioVue OCT-A system and understand the information these images provide.
- Conditions
- Neovascular Age-related Macular Degeneration, Age-related Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion
- Trial name
- NCT02510885
- Testing
- AngioVue SD-OCT
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Duke University
Wet Macular Degeneration
Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration
To assess the efficacy of intravitreal (IVT) administration of aflibercept with two different approaches of Treat and Extend dosing regimens in Japanese subjects with neovascular (wet) Age-related Macular Degeneration (wAMD) .
- Trial name
- ALTAIR (NCT02305238)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- 41 sites in Japan
- Volunteers
- 288 people
- Sponsor
- Bayer
Age-related Macular Degeneration, Cataract
Age-Related Eye Disease Study 2 (AREDS2)
Oral supplementation with the Age-Related Eye Disease Study (AREDS) formulation (antioxidant vitamins C and E, beta carotene, and zinc) has been shown to reduce the risk of progression to advanced age-related macular degeneration…
- Trial name
- AREDS2 (NCT00345176)
- Testing
- Lutein/zeaxanthin, DHA/EPA, Lutein/zeaxanthin and DHA/EPA
- Where
- 91 sites in United States
- Volunteers
- 4,203 people
- Sponsor
- National Eye Institute (NEI)
Age-Related Maculopathy, Age-Related Maculopathies
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
The purpose of this study is to determine the safety and tolerability of multiple doses of RN6G in subjects with advanced dry, age-related macular degeneration including geographic atrophy.
- Conditions
- Age-Related Maculopathy, Age-Related Maculopathies, Eye Diseases, Retinal Degeneration
- Trial name
- NCT01003691
- Testing
- RN6G
- Where
- 24 sites in United States
- Volunteers
- 24 people
- Sponsor
- Pfizer
Macular Degeneration
Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration
This is a safety and efficacy study of abicipar pegol in participants with neovascular age-related macular degeneration.
- Trial name
- NCT02462486
- Testing
- Abicipar Pegol, Ranibizumab
- Where
- 187 sites in United States, Australia and 14 more
- Volunteers
- 949 people
- Sponsor
- Allergan
Macular Degeneration, Choroidal Neovascularization
Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV Associated With AMD
The objectives of this study are to evaluate the safety(first objective) and efficacy(second objective)of an experimental drug product,Stakel®, in the treatment of neovascular Age related Macular Degeneration (AMD).
- Trial name
- NCT01021956
- Testing
- STAKEL
- Where
- 4 sites in United States, France
- Volunteers
- 10 people
- Sponsor
- Steba Biotech S.A.
Retinitis Pigmentosa
Cone Rescue in Retinitis Pigmentosa by the Treatment of Lycium Barbarum
Objectives: To study the immediate effect and the persistent effect of Lycium barbarum (LB) treatment on retinal functions, especially the cone function, and retinal structure in patients with retinitis pigmentosa (RP) Design…
- Trial name
- NCT02244996
- Testing
- Lycium Barbarum
- Where
- Hong Kong
- Volunteers
- 50 people
- Sponsor
- The Hong Kong Polytechnic University
AMD, Wet AMD
INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD
The purpose of this study is to confirm the safety and establish the effectiveness of two doses from the IRay System for the treatment of wet AMD.
- Conditions
- AMD, Wet AMD, Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration
- Trial name
- INTREPID (NCT01016873)
- Testing
- IRay
- Where
- 21 sites in Austria, Czechia and 3 more
- Volunteers
- 230 people
- Sponsor
- Oraya Therapeutics, Inc.
Diabetic Retinopathy, Diabetic Macular Edema
Evaluation of Vitrectomy for Diabetic Macular Edema
The study is designed as a prospective cohort study to assess changes in visual acuity and retinal thickening and surgical complications in subjects undergoing vitrectomy for diabetic macular edema.
- Trial name
- Vitrectomy-D (NCT00709319)
- Where
- 48 sites in United States
- Volunteers
- 87 people
- Sponsor
- Jaeb Center for Health Research
Age Related Macular Degeneration
Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial
The purpose of the study is to evaluate the relative efficacy and safety of treatment of neovascular AMD with Lucentis on a fixed schedule, Avastin on a fixed schedule, Lucentis on a variable schedule, and Avastin on a variable…
- Trial name
- NCT00593450
- Testing
- ranibizumab, bevacizumab
- Where
- 59 sites in United States
- Volunteers
- 1,208 people
- Sponsor
- University of Pennsylvania
Macular Degeneration
Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye
This study aims to evaluate the optimal use, efficacy, and safety of a Treat-and-Extend regimen with aflibercept in subjects with nAMD.
- Trial name
- ARIES (NCT02581891)
- Testing
- Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)
- Where
- 39 sites in Australia, Canada and 6 more
- Volunteers
- 287 people
- Sponsor
- Bayer